Candidiasis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

April 2022 | 169 pages | ID: CDF768705E31EN
Global Markets Direct

Abstracts

Candidiasis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Candidiasis - Drugs In Development, 2022, provides an overview of the Candidiasis (Infectious Disease) pipeline landscape.

Candidiasis is caused by infection with species of the genus Candida, predominantly with Candida albicans. A Candida infection of the skin appears as a clearly defined patch of red, itchy skin, often leaking fluid. Scabs and pustules may be seen around the edge of the rash. It will usually be found in areas such as the groin, the folds of the buttocks, between the breasts, toes, or fingers, and in the navel. Treatment includes anti fungal drugs.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Candidiasis - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Candidiasis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Candidiasis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Candidiasis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 3, 7, 3, 32, 8 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 11 and 8 molecules, respectively.

Candidiasis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Candidiasis (Infectious Disease).
• The pipeline guide reviews pipeline therapeutics for Candidiasis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Candidiasis (Infectious Disease) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Candidiasis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Candidiasis (Infectious Disease)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Candidiasis (Infectious Disease).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Candidiasis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Candidiasis - Overview
Candidiasis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Candidiasis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Candidiasis - Companies Involved in Therapeutics Development
Candidiasis - Drug Profiles
Candidiasis - Dormant Projects
Candidiasis - Discontinued Products
Candidiasis - Product Development Milestones
Featured News & Press Releases
Mar 03, 2022: Rezafungin awarded Promising Innovation Medicine (PIM) Designation by the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) for the treatment of Invasive Candidiasis
Feb 10, 2022: SCYNEXIS announces positive results from its pivotal phase 3 CANDLE study of Oral Ibrexafungerp for prevention of recurrent vaginal yeast infections, clearing the way for regulatory submission and potential approval of additional indication by end of 2022
Dec 20, 2021: BREXAFEMME (ibrexafungerp tablets) added to major national formulary, providing access for millions more commercially insured patients
Dec 15, 2021: Hansoh Pharmaceutical Group announces that clinical trial approval of ibrexafungerp tablets
Dec 15, 2021: European Medicines Agency grants orphan medicinal product designation for SCYNEXIS’ innovative antifungal ibrexafungerp for the indication of invasive candidiasis
Dec 14, 2021: Cidara Therapeutics and Mundipharma announce positive topline results from the global Phase 3 pivotal ReSTORE trial of Rezafungin for the treatment of candidemia and invasive candidiasis
Dec 06, 2021: SCYNEXIS announces agreement with FDA on innovative strategy for approval of oral Ibrexafungerp for treatment of invasive candidiasis
Dec 01, 2021: BREXAFEMME (Ibrexafungerp Tablets) receives 2021 popular science best of what’s new award in the health category
Nov 29, 2021: SCYNEXIS to host Ibrexafungerp hospital pipeline update Call and KOL webcast for investors on December
Nov 24, 2021: Scynexis reports positive data from Phase III oral VVC treatment trial
Nov 09, 2021: SCYNEXIS announces successful completion of phase 1 trial evaluating intravenous (IV) formulation of ibrexafungerp
Nov 08, 2021: FDA grants Profounda Orphan Drug Designation approval for treatment of treatment of invasive candidiasis with miltefosine
Nov 04, 2021: Hengrui Medicine's Class 1 new drug SHR8008 for the treatment of fungal vaginitis will be submitted for marketing application
Nov 03, 2021: Mycovia Pharmaceuticals announces completion of partner Jiangsu Hengrui Pharmaceuticals’ Phase 3 clinical study evaluating oteseconazole for treatment of acute vulvovaginal candidiasis (VVC) in China
Nov 02, 2021: Hyloris announces start of phase 2 study of Miconazole-Domiphen Bromide Vaginal Cream in vulvovaginal candidiasis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Candidiasis, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Companies, 2022 (Contd..1)
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Candidiasis - Pipeline by AbGenics Life Sciences Pvt Ltd, 2022
Candidiasis - Pipeline by Autoimmune Technologies LLC, 2022
Candidiasis - Pipeline by Bakker Medical Srl, 2022
Candidiasis - Pipeline by Beta Pharma Inc, 2022
Candidiasis - Pipeline by Biokawthar Technologies SAS, 2022
Candidiasis - Pipeline by Biomendics LLC, 2022
Candidiasis - Pipeline by Biosergen AS, 2022
Candidiasis - Pipeline by Cidara Therapeutics Inc, 2022
Candidiasis - Pipeline by CSA Biotechnologies LLC, 2022
Candidiasis - Pipeline by CSPC Pharmaceutical Group Ltd, 2022
Candidiasis - Pipeline by Destiny Pharma Plc, 2022
Candidiasis - Pipeline by Fox Chase Chemical Diversity Center Inc, 2022
Candidiasis - Pipeline by FUJIFILM Toyama Chemical Co Ltd, 2022
Candidiasis - Pipeline by General Biologicals Corp, 2022
Candidiasis - Pipeline by Grupo Ferrer Internacional SA, 2022
Candidiasis - Pipeline by Hennepin Life Sciences LLC, 2022
Candidiasis - Pipeline by Knight Therapeutics Inc, 2022
Candidiasis - Pipeline by Matinas BioPharma Holdings Inc, 2022
Candidiasis - Pipeline by MicroRid Technologies Inc, 2022
Candidiasis - Pipeline by Mycovia Pharmaceuticals Inc, 2022
Candidiasis - Pipeline by Nanomerics Ltd, 2022
Candidiasis - Pipeline by Next Science Ltd, 2022
Candidiasis - Pipeline by Nosopharm SAS, 2022
Candidiasis - Pipeline by Novabiotics Ltd, 2022
Candidiasis - Pipeline by Novartis AG, 2022
Candidiasis - Pipeline by Oryn Therapeutics, 2022
Candidiasis - Pipeline by Osel Inc, 2022
Candidiasis - Pipeline by Pacgen Life Science Corp, 2022
Candidiasis - Pipeline by Pfizer Inc, 2022
Candidiasis - Pipeline by Profem GmbH, 2022
Candidiasis - Pipeline by Pulmocide Ltd, 2022
Candidiasis - Pipeline by Pulmonomy Inc, 2022
Candidiasis - Pipeline by Purna Female Healthcare, 2022
Candidiasis - Pipeline by REYON Pharmaceutical Co Ltd, 2022
Candidiasis - Pipeline by Riptide Bioscience Inc, 2022
Candidiasis - Pipeline by Sano Chemicals Inc, 2022
Candidiasis - Pipeline by Satellos Bioscience Inc, 2022
Candidiasis - Pipeline by Scynexis Inc, 2022
Candidiasis - Pipeline by Shaanxi Synthetic Pharmaceutical Co Ltd, 2022
Candidiasis - Pipeline by Stadius Biopharma LLC, 2022
Candidiasis - Pipeline by TGV Therapeutics, 2022
Candidiasis - Pipeline by Toltec Pharmaceuticals LLC, 2022
Candidiasis - Pipeline by Visterra Inc, 2022
Candidiasis - Pipeline by Wellstat Vaccines LLC, 2022
Candidiasis - Dormant Projects, 2022
Candidiasis - Discontinued Products, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development for Candidiasis, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022